Subscribe
istock-504614468_brauns
brauns / iStockphoto.com
10 January 2019Americas

Gilead announces licence and collaboration deal with Yuhan

Gilead Sciences, a biopharmaceutical company based in the US, has entered into a licensing and collaboration agreement with South Korean healthcare company Yuhan.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
South Korean global licensing spikes n 2018
22 January 2019   South Korean pharmaceutical companies entered into 11 out-licensing deals with overseas partners in 2018, according to the country’s Ministry of Health and Welfare.
Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Americas
Gilead signs immuno-oncology deal with Tango
2 November 2018   California-based Gilead Sciences has signed a collaboration agreement with Tango Therapeutics to discover and develop a pipeline of immuno-oncology treatments for cancer patients.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Asia-Pacific
South Korean global licensing spikes n 2018
22 January 2019   South Korean pharmaceutical companies entered into 11 out-licensing deals with overseas partners in 2018, according to the country’s Ministry of Health and Welfare.
Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Americas
Gilead signs immuno-oncology deal with Tango
2 November 2018   California-based Gilead Sciences has signed a collaboration agreement with Tango Therapeutics to discover and develop a pipeline of immuno-oncology treatments for cancer patients.

More on this story

Asia-Pacific
South Korean global licensing spikes n 2018
22 January 2019   South Korean pharmaceutical companies entered into 11 out-licensing deals with overseas partners in 2018, according to the country’s Ministry of Health and Welfare.
Big Pharma
German patent court publishes reasoning in Gilead SPC dispute
6 November 2018   Germany’s Federal Patent Court has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate for HIV/AIDS treatment Truvada,
Americas
Gilead signs immuno-oncology deal with Tango
2 November 2018   California-based Gilead Sciences has signed a collaboration agreement with Tango Therapeutics to discover and develop a pipeline of immuno-oncology treatments for cancer patients.

More features

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era
Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC